Occam Places Nick Pullen as CSO of ARTBIO

Occam continues its track record of company building with the placement of Nick Pullen, PhD as CSO of ARTBIO, a clinical-stage radiopharmaceutical play developing a new class of targeted alpha radioligand therapies. Pullen will join forces with Emanuele Ostuni, the CEO, whom Occam also placed last year.

‍

Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. Prior to joining ARTBIO, Pullen served as SVP and Head of Research at Jnana. There he participated in their Series B and C fundraisings that together raised >$150 million; led a multi-target partnership with Roche; built a discovery pipeline; and put into development a first-in-class SLC6A19 allosteric inhibitor for the treatment of PKU. Before Jnana, Pullen was Vice President of Integrative Sciences at Celgene/BMS, and prior to that, he worked at Pfizer in several scientific leadership positions. Across both companies, Pullen was responsible for scientific and strategic leadership for many drug discovery programs.